ストックスクリーナーアプリを入手
0.9469
0.33%
-0.0031
前日終値:
$0.95
開ける：
$0.9521
24時間の取引高:
189.33K
Relative Volume:
0.70
時価総額：
$20.45M
収益：
-
当期純損益:
$-8.32M
株価収益率:
-1.9662
EPS:
-0.4816
ネットキャッシュフロー:
$-7.43M
1週間 パフォーマンス:
-15.46%
1か月 パフォーマンス:
-8.07%
6か月 パフォーマンス:
-32.36%
1年 パフォーマンス:
-26.02%
1日の値動き範囲:
$0.9301
$0.9791
1週間の範囲:
$0.9301
$1.11
52週間の値動き範囲:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Compare NNVC vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
0.9469 | 20.52M | 0 | -8.32M | -7.43M | -0.4816 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-16 | 開始されました | Alliance Global Partners | Buy |
| 2015-02-11 | 開始されました | Midtown Partners | Strong Buy |
NanoViricides Inc (NNVC) 最新ニュース
Aug Retail: Can NanoViricides Inc generate free cash flowEarnings Beat & Real-Time Volume Analysis - baoquankhu1.vn
NanoViricides (NYSE:NNVC) Stock Price Down 4.8% – What’s Next? - Defense World
If You Invested $1,000 in Nanoviricides (NNVC) - Stock Titan
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
EBITDA per share of NanoViricides, Inc. – FWB:NV3P - TradingView
Volume Recap: Can NanoViricides Inc grow without external funding2026 Momentum Check & Consistent Return Strategy Ideas - baoquankhu1.vn
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Beaver County Times
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides - The Register-Guard
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - The Asheville Citizen Times
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete - ACCESS Newswire
NanoViricides Completes Manufacturing of NV-387 Oral Gummies, Prepares for Phase II Monkeypox Trial - citybuzz -
Aug Setups: Can NanoViricides Inc continue delivering strong returns2026 EndofMonth & Stepwise Trade Execution Plans - baoquankhu1.vn
Small cap wrap: NanoViricides, Millennial Potash, Gunnison Copper, Century Lithium… - Proactive Investors
NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial - Yahoo! Finance Canada
Antiviral NV-387 heads to Phase II mpox trial with new gummy form - Stock Titan
Jobs Data: Can NanoViricides Inc continue delivering strong returnsMarket Volume Report & Community Verified Trade Signals - baoquankhu1.vn
Sell Signal: Is NanoViricides Inc subject to activist investor interest2025 Investor Takeaways & Low Risk Growth Stock Ideas - baoquankhu1.vn
NNVC Earnings History & Surprises | EPS & Revenue Results | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 - The Asheville Citizen Times
getLinesFromResByArray error: size == 0 What is NanoViricides Inc.’s TAM (Total Addressable Market)Portfolio Gains Report & Growth Focused Entry Reports - mfd.ru
US Stocks Recap: Is NanoViricides Inc forming a breakout patternJuly 2025 WrapUp & Community Trade Idea Sharing - baoquankhu1.vn
Aug Fed Impact: Can NanoViricides Inc continue delivering strong returnsQuarterly Earnings Report & Long-Term Safe Investment Plans - baoquankhu1.vn
NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387ICYMI - Proactive financial news
Growth Value: Will NanoViricides Inc benefit from rate cutsJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Small cap wrap: Aftermath Silver, M2i Global, NanoViricides, AtaiBeckley… - Proactive financial news
NanoViricides advances toward fully funded Phase II MPox trial in DRC - Proactive financial news
NanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox study - Yahoo Finance
NanoViricides: Fiscal Q2 Earnings Snapshot - kare11.com
NanoViricides: Fiscal Second Quarter Earnings Overview - Bitget
Moving Averages: Is NanoViricides Inc exposed to political riskJuly 2025 Movers & Growth Focused Stock Reports - baoquankhu1.vn
Can NanoViricides Inc grow without external fundingJuly 2025 Review & Growth Focused Stock Reports - baoquankhu1.vn
Small cap wrap: BioVie, VivoPower, NanoViricides, Aftermath Silver... - Proactive financial news
NanoViricides seeks FDA orphan status for MPox drug - Yahoo Finance
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Bitget
New Mpox drug candidate NV-387 chases FDA orphan status - Stock Titan
NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX) - Barchart.com
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza WaveNV-387 is Effective Against H3N2 - Ventura County Star
Small cap wrap: Medicus Pharma, 1911 Gold, NanoViricides, Nextech3D.ai, NextSource Materials… - Proactive Investors
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - USA Today
NanoViricides seeks orphan drug status with US FDA for measles treatment - Yahoo Finance
Measles cases surge as NanoViricides seeks orphan status for NV-387 - Stock Titan
NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres - USA Today
NanoViricides Inc (NNVC) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):